

## Medical Breast Training Program

<b>Session Four: Management of a High-Risk Patient</b>	
<p><b>Course Description:</b> During session four you will discuss the management of patients identified to be at high risk for breast cancer. You will understand the imaging modalities used in enhanced screening and surveillance for this patient population, and when genetic testing is appropriate. Additionally, you will develop an approach to supporting patients in reducing their overall risk of breast cancer through lifestyle, medication, or surgical intervention.</p>	
<p>Learning Objectives:</p> <ul style="list-style-type: none"> <li>• Discuss the management of patients with biopsy-proven high-risk breast lesions, a strong family history of breast cancer, or identified gene mutations that significantly increase risk of breast cancer.</li> <li>• Understand the role of enhanced screening and surveillance imaging, and genetic testing.</li> <li>• Develop an approach to breast cancer risk mitigation strategies including lifestyle modifications, risk-reducing pharmacotherapy, or preventative surgery.</li> </ul>	
30 Minute	<p>Atypical Hyperplasia <i>Mary M. Mrdutt, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Describe atypical hyperplasia in terms of clinical or radiological presentation</li> <li>• Define risk associated with atypical hyperplasia</li> <li>• Briefly discuss management strategies including the role of high-risk screening imaging, risk reduction strategies (*pharmacotherapy will be covered in detail in a separate talk)</li> </ul>
30 Minute	<p>Lobular Carcinoma In Situ <i>David W. Lim, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Define and describe lobular carcinoma in situ (LCIS), the risk associated with LCIS, and how it differs from ductal carcinoma in situ</li> <li>• Discuss management strategies for LCIS</li> <li>• Briefly discuss risk-reduction strategies as they apply to LCIS including lifestyle recommendations and enhanced screening considerations (*pharmacotherapy will be covered in detail in a separate talk)</li> </ul>
30 Minute	<p>Preventive Medication <i>Sandhya Pruthi, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Review the evidence for risk reducing preventative pharmacotherapy and the different options available</li> <li>• Review risks and benefits for risk reducing pharmacotherapy</li> <li>• Define the populations who benefit from risk reducing medication</li> <li>• Review how to prescribe and monitor patients who are on preventative medication to decrease risk of breast cancer</li> </ul>
30 Minute	<p>Enhanced Surveillance Imaging <i>Ellen Warner, M.D., FRCPC, FACP, M.Sc.</i></p>

	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Review the evidence for enhanced surveillance screening imaging</li> <li>• Discuss the different modalities used in high-risk screening - (<u>digital mammography, digital breast tomosynthesis and MRI</u>), <u>sensitivity and specificity of each and possible risks/benefits.</u></li> <li>• Discuss best practices as to which patient populations should participate in enhanced screening imaging, recommended interval for screening, and what to do during pregnancy/breastfeeding</li> </ul>
30 Minute	<p>Risk Reduction – Bilateral Prophylactic Mastectomy <i>Zahraa AlHilli, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Review the evidence for bilateral prophylactic mastectomy</li> <li>• Define the patient population that should be considered for bilateral prophylactic mastectomy</li> <li>• Educate participants on the surgical process, risks, and benefits, including common post-operative considerations that patients may experience</li> </ul>
30 Minute	<p>Risk Reduction – Bilateral Salpingo-Oophorectomy <i>Mariam AlHilli, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Review the evidence for bilateral salpingo-oophorectomy</li> <li>• Define the patient population that should be considered for bilateral salpingo-oophorectomy</li> <li>• Educate participants on the surgical process, risks, and benefits, including common post-operative considerations that patients may experience</li> </ul>
30 Minute	<p>Lifestyle Modification and Primary Breast Cancer Prevention <i>Dawn M. Mussallem, D.O.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> <li>• Define modifiable breast cancer risk factors</li> <li>• Review lifestyle considerations (diet, exercise, alcohol etc) in breast cancer risk management and their effect on breast cancer risk.</li> <li>• Describe a practical approach to clinical counselling around primary breast cancer prevention</li> </ul>
<p><b>Livestream</b> <b>June 4, 2022</b> <b>9:00 a.m. –</b> <b>12:00 p.m. CT</b></p>	<p>Risk Assessment, Genetics, Management of High-Risk Patients Case Discussions (5) <b>Melinda Wu, M.D., Holly Pederson, M.D., Juliana (Jewel) M. Kling, M.D., M.P.H., David W. Lim, M.D., Aletta Poll, M.Sc., Sandhya Pruthi, M.D.</b></p>